Ming-Tao Yang

Dr. Ming-Tao Yang

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
YLYun-Chia Liang
Yun-Chia Liang
IWIven Wijaya
Iven Wijaya
MYMing-Tao Yang
Ming-Tao Yang
JJJosue Rodolfo Cuevas Juarez
Josue Rodolfo Cuevas Juarez
HCHou-Tai Chang
Hou-Tai Chang
Recognizing why an infant cries is challenging as babies cannot communicate verbally with others to express their wishes or needs. This leads to difficulties for parents in identifying the needs and the health of their infants. This study used deep learning (DL) algorithms such as the convolutional neural network (CNN) and long short-term memory (LSTM) to recognize infants’ necessities such as hunger/thirst, need for a diaper change, emotional needs (e.g., need for touch/holding), and pain caused by medical treatment (e.g., injection). The classical artificial neural network (ANN) was also used for comparison. The inputs of ANN, CNN, and LSTM were the features extracted from 1607 10 s audio recordings of infants using mel-frequency cepstral coefficients (MFCC). Results showed that CNN and LSTM both provided decent performance, around 95% in accuracy, precision, and recall, in differentiating healthy and sick infants. For recognizing infants’ specific needs, CNN reached up to 60% accuracy, outperforming LSTM and ANN in almost all measures. These results could be applied as indicators for future applications to help parents understand their infant’s condition and needs.

21 January 2017 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
MYMing-Tao Yang
Ming-Tao Yang
YLYi-Chin Lin
Yi-Chin Lin
WHWhae-Hong Ho
Whae-Hong Ho
CLChao-Lin Liu
Chao-Lin Liu
WLWang-Tso Lee
Wang-Tso Lee
Microglia is responsible for neuroinflammation, which may aggravate brain injury in diseases like epilepsy. Mammalian target of rapamycin (mTOR) kinase is related to microglial activation with subsequent neuroinflammation. In the present study, rapamycin and everolimus, both as mTOR inhibitors, were investigated in models of kainic acid (KA)-induced seizure and lipopolysaccharide (LPS)-induced neuroinflammation. In vitro, we treated BV2 cells with KA and LPS. In vivo, KA was used to induce seizures on postnatal day 25 in B6.129P-Cx3cr1tm1Litt/J mice. Rapamycin and everolimus were evaluated in their modulation of neuroinflammation detected by real-time PCR, Western blotting, and immunostaining. Everolimus was significantly more effective than rapamycin in inhibiting iNOS and mTOR signaling pathways in both models of neuroinflammation (LPS) and seizure (KA). Everolimus significantly attenuated the mRNA expression of iNOS by LPS and nitrite production by KA and LPS than that by rapamycin. Only everolimus attenuated the mRNA expression of mTOR by LPS and KA treatment. In the present study, we also found that the modulation of mTOR under LPS and KA treatment was not mediated by Akt pathway but was primarily mediated by ERK phosphorylation, which was more significantly attenuated by everolimus. This inhibition of ERK phosphorylation and microglial activation in the hippocampus by everolimus was also confirmed in KA-treated mice. Rapamycin and everolimus can block the activation of inflammation-related molecules and attenuated the microglial activation. Everolimus had better efficacy than rapamycin, possibly mediated by the inhibition of ERK phosphorylation. Taken together, mTOR inhibitor can be a potential pharmacological target of anti-inflammation and seizure treatment.

1 April 2013 in Neuropharmacology
Verified
Journal Article
Closed access
MYMing-Tao Yang
Ming-Tao Yang
WCWei-Lin Chien
Wei-Lin Chien
DLDai-Hua Lu
Dai-Hua Lu
HLHoung-Chi Liou
Houng-Chi Liou
WFWen-Mei Fu
Wen-Mei Fu

1 June 2020 in Biomedical Journal
Verified
Journal Article
Open access
MYMing-Tao Yang
Ming-Tao Yang
Neurocritical monitoring is important in caring for patients in the neurological intensive care unit. Although clinical neurologic examination is standard for neurocritical monitoring, changes found during the examination are often late signs and insufficient to detect and prevent secondary brain injury. Therefore, various neuromonitoring tools have been developed to monitor different physiologic parameters, such as cerebral oxygenation, cerebral blood flow, cerebral pressure, cerebral autoregulation, cerebral electric activity, and cerebral metabolism. In this review, we have discussed current commonly used neurocritical monitoring tools. No single monitor is sufficient and perfect for neurocritical monitoring. Multimodal neurocritical monitoring is the current trend. However, the lack of common formatting standards and uncertainty of improvement in patients' outcomes warrant further studies of multimodal neurocritical monitoring. Nevertheless, multimodal neurocritical monitoring considers individual pathophysiological variations in patients or their injuries and allows clinicians to tailor individualized management decisions.

Verified
Journal Article
Open access
PDF file
Hueng-Chuen FanHueng-Chuen Fan
Hueng-Chuen Fan
MYMing-Tao Yang
Ming-Tao Yang
LLLungchang Lin
Lungchang Lin
KCKuo-Liang Chiang
Kuo-Liang Chiang
Chuan-Mu ChenChuan-Mu Chen
Chuan-Mu Chen
Dravet syndrome (DS), also known as severe myoclonic epilepsy of infancy, is a rare and drug-resistant form of developmental and epileptic encephalopathies, which is both debilitating and challenging to manage, typically arising during the first year of life, with seizures often triggered by fever, infections, or vaccinations. It is characterized by frequent and prolonged seizures, developmental delays, and various other neurological and behavioral impairments. Most cases result from pathogenic mutations in the sodium voltage-gated channel alpha subunit 1 (SCN1A) gene, which encodes a critical voltage-gated sodium channel subunit involved in neuronal excitability. Precision medicine offers significant potential for improving DS diagnosis and treatment. Early genetic testing enables timely and accurate diagnosis. Advances in our understanding of DS’s underlying genetic mechanisms and neurobiology have enabled the development of targeted therapies, such as gene therapy, offering more effective and less invasive treatment options for patients with DS. Targeted and gene therapies provide hope for more effective and personalized treatments. However, research into novel approaches remains in its early stages, and their clinical application remains to be seen. This review addresses the current understanding of clinical DS features, genetic involvement in DS development, and outcomes of novel DS therapies.

26 December 2022 in Epilepsy & Behavior
Verified
Journal Article
Closed access
MYMing-Tao Yang
Ming-Tao Yang
ICI-Ching Chou
I-Ching Chou
HWHuei-Shyong Wang
Huei-Shyong Wang